...
首页> 外文期刊>Radiation Research: Official Organ of the Radiation Research Society >INHIBITION OF RADIATION CATARACTOGENESIS BY WR-77913
【24h】

INHIBITION OF RADIATION CATARACTOGENESIS BY WR-77913

机译:WR-77913抑制放射致癌作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The radioprotective drug S-3-amino-2-hydroxypropylphosphorothioic acid (WR-77913) has been tested as an inhibitor of radiation cataractogenesis. Animals treated with 15 Gy whole-head Cs-137 gamma radiation developed mature cataracts 10-12 weeks after irradiation. Intraperitoneal pretreatment with 815 mg/kg WR-77913 30 min before irradiation delayed the development of cataracts; mature cataracts required 42 weeks for development. Doses as low as 350 mg/kg, substantially below the toxic range, resulted in graded but incomplete protection and a significant delay in the development of cataracts. Drug treatment combined with radiation doses of 12.5 or 10 Gy showed less pronounced protection. The optimum time of drug delivery was found to be between 30 min and 2 h before irradiation; protective action diminished if longer times were used or if the drug was given after irradiation. These results are discussed in relation to those obtained with other chemical radioprotective agents and in terms of possible mechanisms of the action of the drug. [References: 55]
机译:辐射防护药物S-3-氨基-2-羟丙基硫代磷酸(WR-77913)已被测试为放射性白内障的抑制剂。用15 Gy全头Cs-137γ射线治疗的动物在辐射后10-12周发育成熟的白内障。辐照前30分钟用815 mg / kg WR-77913进行腹膜内预处理可延迟白内障的发展;成熟的白内障需要42周才能发育。剂量低至350 mg / kg,大大低于毒性范围,导致分级的但不完全的保护,并显着延缓了白内障的发生。药物治疗与12.5或10 Gy的辐射剂量相结合显示出较不明显的保护作用。发现最佳的药物递送时间是在照射前30分钟至2小时之间。如果使用更长的时间或如果在辐射后使用药物,则保护作用减弱。这些结果是关于用其他化学放射防护剂获得的结果以及药物作用的可能机理进行了讨论。 [参考:55]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号